151. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.
- Author
-
Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, and Khanna R
- Subjects
- Adult, B-Lymphocytes immunology, Brain immunology, Brain pathology, CD8-Positive T-Lymphocytes immunology, Disease Progression, Epstein-Barr Virus Infections immunology, Humans, Male, Multiple Sclerosis, Chronic Progressive complications, CD8-Positive T-Lymphocytes virology, Epstein-Barr Virus Infections therapy, Herpesvirus 4, Human immunology, Immunotherapy, Adoptive, Multiple Sclerosis, Chronic Progressive virology
- Abstract
Defective control of Epstein-Barr virus (EBV) infection by cytotoxic CD8(+) T cells might predispose to multiple sclerosis (MS) by allowing EBV-infected autoreactive B cells to accumulate in the central nervous system. We have treated a patient with secondary progressive MS with in vitro-expanded autologous EBV-specific CD8(+) T cells directed against viral latent proteins. This adoptive immunotherapy had no adverse effects and the patient showed clinical improvement with reduced disease activity on magnetic resonance imaging and decreased intrathecal immunoglobulin production. This is the first report of the use of EBV-specific adoptive immunotherapy to treat MS or any other autoimmune disease., (© The Author(s) 2014.)
- Published
- 2014
- Full Text
- View/download PDF